CXCL4 and CXCL7 serum levels are decreased in MDS patients [101]; although this decrease was more pronounced in patients with advanced disease, it was also detectable in early stage MDS and may therefore be of diagnostic relevance. This evidence concerns the gene PF4 and myelodysplastic syndrome.